iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Additional studies presented at ACC.23/WCC reinforce the clinical value of the Zio suite of products and services Additional studies presented at ACC.23/WCC reinforce the clinical value of the Zio suite of products and services

Large Real-World Evidence Analysis Demonstrates that Zio® XT Is Associated With the Highest Diagnostic Yield, Lowest Retesting Rates, and Fastest Time to Clinical Diagnosis Compared to Other Ambulatory ECG Monitors

iRhythm continues to expand its strong body of clinical and scientific evidence with new research presented by leading clinical investigators at the conference

Four New Studies Featuring Zio® by iRhythm to be Presented at ACC.23/WCC

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor Relations Quentin Blackford - President & Chief Executive Officer Brice Bobzien - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Marie Thibault - BTIG Cecilia Furlong - Morgan Stanley David Saxon - Needham Nathan Treybeck - Wells Fargo David Rescott - Truist Securities Suraj Kalia - Oppenheimer Michael Polark - Wolfe Research Operator Good afternoon. Thank you for attending today's iRhythm, Inc. Q4 2022 Earnings Conference Call.

iRhythm Technologies, Inc. (IRTC) Q4 2022 Earnings Call Transcript

SAN FRANCISCO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2022.

iRhythm Technologies Announces Fourth Quarter and Full Year 2022 Financial Results

SAN FRANCISCO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2022 after the close of trading on Thursday, February 23, 2023. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT/4:30 p.m. ET.

iRhythm Technologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 41st Annual J.P. Morgan Healthcare Conference.

iRhythm Technologies Shares Preliminary Fourth Quarter 2022 Highlights and Business Update at the 41st Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

iRhythm® Technologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio® suite of products across a range of clinical applications Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio® suite of products across a range of clinical applications

Results of Four Studies Demonstrating Clinical, Economic Value of iRhythm's Product Portfolio Presented at American Heart Association '22

A new analysis of iRhythm's mSToPS trial, presented at the American Heart Association, reveals that Zio® XT provided high value from a health economic perspective A new analysis of iRhythm's mSToPS trial, presented at the American Heart Association, reveals that Zio® XT provided high value from a health economic perspective

New Research Confirms that Zio® by iRhythm Provides High Value From a Health Economic Perspective

SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today provided commentary on the recently released Centers for Medicare and Medicaid Services (“CMS”) Medicare Physician Fee Schedule (“MPFS”) Final Rule for Calendar Year 2023 and accompanying addenda (the “Final Rule”). The Final Rule was released on November 2, 2022 and updated payment policies, payment rates and other provisions for services furnished on or after January 1, 2023, which include those rates related to long term electrocardiogram (“ECG”) monitoring and recording that iRhythm uses to seek reimbursement for its Zio® XT service.

iRhythm® Technologies Comments on the Final Medicare Physician Fee Schedule Released by the Centers for Medicare and Medicaid Services for Calendar Year 2023

SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today commented on the recent announcement from the Centers for Medicare and Medicaid Services (“CMS”) that it has issued the Medicare Physician Fee Schedule (MPFS) Final Rule for Calendar Year 2023 (the “Final Rule”). On November 1, 2022, CMS stated in its fact sheet that the Final Rule includes payment policies, payment rates and other provisions for services furnished on or after January 1, 2023 (“CMS Fact Sheet”).

iRhythm® Technologies Comments on the Announcement of the Medicare Physician Fee Schedule Final Rule Released by the Centers for Medicare and Medicaid Services for Calendar Year 2023

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor Relations Quentin Blackford - President and Chief Executive Officer Brice Bobzien - Chief Financial Officer Douglas Devine - Chief Operating Officer Daniel Wilson - Executive Vice President of Strategy and Corporate Development Conference Call Participants Margaret Kaczor - William Blair & Co. LLC Allen Gong - JPMorgan Chase & Co. Cecilia Furlong - Morgan Stanley David Rescott - Truist Securities, Inc. Joanne Wuensch - Citigroup Inc. David Saxon - Needham & Company, LLC William Plovanic - Canaccord Genuity Corp. Suraj Kalia - Oppenheimer & Co. Inc. Michael Polark - Wolfe Research, LLC Operator Hello, and welcome to today's iRhythm Technologies, Inc. Q3 2022 Earnings Conference Call. My name is Elliot, and I'll be coordinating your call today.

iRhythm Technologies, Inc. (IRTC) Q3 2022 Earnings Call Transcript

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 23.17% and 2.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IRhythm Technologies (IRTC) Reports Q3 Loss, Misses Revenue Estimates

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported financial results for the three months ended September 30, 2022.

iRhythm Technologies Announces Third Quarter 2022 Financial Results

FANUC Corp

IPG Photonics

Intuitive Surgical

NVIDIA

UiPath

Teradyne

The robotics industry has been growing at an incredible pace, and the computing power needed for these mechatronic devices is getting cheaper by the day. The increased computing power and data handling capabilities of mechatronic devices are allowing them new actions that previously weren't possible for humans.

7 Robotic Stocks to Buy for the Coming Robot Boom

Calumet Inc

Hudson Technologies

Karuna Therapeutics Inc

Lantheus Holdings

Liquidia Technologies Inc

Veru

Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement of a stock or sector.

7 Momentum Stocks to Buy Now for Extraordinary Gains

SAN FRANCISCO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent and predict disease, will discuss the Company's strategies for long-term growth, provide an update on its innovation pipeline and share its financial goals during its 2022 Analyst & Investor Day today in New York City. A live webcast of the event will begin at 9:00 a.m. ET and will be accessible at that time on the investors section of the Company's website at investors.irhythmtech.com.

iRhythm Technologies Details Growth Strategies at 2022 Analyst & Investor Day

SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the Company will host an Analyst & Investor Day on Wednesday, September 21, 2022, in New York City.

iRhythm Technologies to Host Analyst & Investor Day on September 21, 2022

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor Relations Quentin Blackford - President and Chief Executive Officer Doug Devine - Chief Operating Officer and Chief Financial Officer Dan Wilson - EVP of Corporate Strategy and Development Conference Call Participants Calvin Chu - Morgan Stanley Allen Gong - JPMorgan Joanne Wuensch - Citi Brandon Vazquez - William Blair David Rescott - Truist Securities Marie Thibault - BTIG Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Michael Polark - Wolfe Research Operator Good afternoon, everybody, and welcome to today's iRhythm Technologies, Inc. Q2 2022 Earnings Conference Call. My name is Drew, and I'll be coordinating your call today.

iRhythm Technologies, Inc. (IRTC) CEO Quentin Blackford on Q2 2022 Results - Earnings Call Transcript

SAN FRANCISCO, July 28, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming Canaccord Genuity 42nd Annual Growth Stock Conference.

iRhythm Technologies to Present at the Canaccord Genuity 42nd Annual Growth Conference

IRhythm Technologies (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate iRhythm Technologies (IRTC) to Report a Decline in Earnings: What to Look Out for

SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of two seasoned executives to its leadership team. Brice Bobzien will join the company as the Chief Financial Officer on August 8, 2022, to lead all financial operations of the company as well as to advance the culture of operational excellence and prepare the company for future growth. Reyna Fernandez will join as the company's Executive Vice President, Chief Human Resources Officer on July 25, 2022, to lead the development and implementation of human resources strategies in support of the company's global expansion plans.

iRhythm Technologies Announces the Addition of Two Executive Leaders to Advance Strategic Growth and Operational Excellence

Developed in partnership with Verily, the Zio® Watch and the ZEUS System combine to create a clinical grade watch to detect and characterize AFib and integrate with clinician's workflow Developed in partnership with Verily, the Zio® Watch and the ZEUS System combine to create a clinical grade watch to detect and characterize AFib and integrate with clinician's workflow

iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System

SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that Dave Vort, the Company's Chief Commercial Officer, has resigned effective July 25, 2022. To support continued growth and ongoing implementation of iRhythm's commercial strategy, Mr. Vort will continue to serve the Company as a strategic advisor and actively engage with the Company's leadership team through March 31, 2023.

iRhythm Technologies Announces Chief Commercial Officer Transition and Schedules Second Quarter Earnings Release and Conference Call for August 4, 2022

Kura Sushi USA

A mixed day for major indexes didn't hold these companies back.

News for iRhythm Technologies Stock (IRTC)